Clinical trials: Eyes With Retinal Disease
Age-Related Macular Degeneration
Ocular, Vascular, and Genetic Findings in AMD Patients
Observation of findings associated with AMD
- Trial name
- NCT06015633
- Testing
- No intervention
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- OcuDyne, Inc.
Age Related Macular Degeneration, Choroidal Neovascularization
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
The study will be designed as a case control evaluation to compare the genetic profiles of three groups of patients categorized according to diagnosis.
- Conditions
- Age Related Macular Degeneration, Choroidal Neovascularization, Central Serous Chorioretinopathy
- Trial name
- NCT01880788
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Sequenom, Inc.
Retinitis Pigmentosa, Retinitis Pigmentosa Syndrome
Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa
This is an open-label, multiple ascending dose study to evaluate the safety, tolerability, and efficacy of EA-2353 in subjects with RP. Unilateral intravitreal injections (IVT) will be administered into the subject's Study Eye.
- Trial name
- NCT05392751
- Testing
- EA-2353
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- Endogena Therapeutics, Inc
Retinal Neovascularization
Home OCT Guided Management Study of Subjects Diagnosed With Neovascular-AMD
During the last 25 years, OCT has become one of the most common imaging technologies used to diagnose and monitor retinal diseases, including AMD.
- Trial name
- NCT05650047
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Notal Vision Inc.
Geographic Atrophy
A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy
This study is being conducted in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) to determine if intravitreal (IVT) injections of ANX007 reduce GA lesion growth rate.
- Trial name
- ARCHER (NCT04656561)
- Testing
- ANX007
- Where
- 53 sites in United States, Australia and 1 more
- Volunteers
- 270 people
- Sponsor
- Annexon, Inc.
Diabetic Macular Edema, Diabetic Retinopathy
ADVM-022 Intravitreal Gene Therapy for DME
A Phase 2, Multi-Center, Randomized, Double-Masked*, Active Controlled Study of ADVM-022 (AAV.7m8-aflibercept) in Subjects with Diabetic Macular Edema [INFINITY]
- Trial name
- INFINITY (NCT04418427)
- Testing
- 6E11 vg/eye of ADVM-022, 2E11 vg/eye of ADVM-022, Aflibercept
- Where
- 14 sites in United States, Puerto Rico
- Volunteers
- 36 people
- Sponsor
- Adverum Biotechnologies, Inc.
Visual Impairment
Post-market Evaluation of OdySight App to Monitor Near Visual Acuity at Home (TIL002)
OdySight is a mobile application allowing self-testing of visual parameters including near visual acuity and communication of the data to an online dashboard to patient's doctors.
- Trial name
- TIL002 (NCT05510479)
- Testing
- Software as medical device
- Where
- 3 sites in France
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Tilak Healthcare
Macular Degeneration
Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)
This study examines the effect of intravitreally administered VEGF Trap in patients with wet AMD. The purpose of this trial is to assess the ocular and systemic safety and tolerability of repeated intravitreal doses of VEGF Trap…
- Trial name
- NCT00320788
- Testing
- aflibercept injection (VEGF Trap-Eye, BAY86-5321)
- Where
- 18 sites in United States
- Volunteers
- 159 people
- Sponsor
- Regeneron Pharmaceuticals
Cytomegalovirus Retinitis, HIV Infections
A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis
The purpose of this study is to see if it is safe and effective to give Viracept to AIDS patients who are already being treated for cytomegalovirus (CMV) retinitis.
- Trial name
- NCT00002169
- Testing
- Nelfinavir mesylate
- Where
- 8 sites in United States
- Sponsor
- Agouron Pharmaceuticals
Retinitis Pigmentosa
A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa
The main purpose of this study is to evaluate the preliminary safety and immunogenicity (ability of an antigen to provoke immune response in the human body) of CNTO 2476, administered subretinally, in participants with advanced…
- Trial name
- NCT00458575
- Testing
- CNTO 2476
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Centocor, Inc.
Diabetic Retinopathy, Diabetic Macular Edema
Prevalence of DIAbetic RETinopathy and Impact of Genetic Factors in the Development of Diabetic Retinopathy of Patients With Type 1 and 2 Diabetes Mellitus in SlovaKia
The aim of the study is to find out prevalence and individual stages of Diabetic Retinopathy in patients with type 1 and type 2 DM verified based on complex ophthalmologic measurements in Slovak Republic.
- Conditions
- Diabetic Retinopathy, Diabetic Macular Edema, Diabetes Mellitus
- Trial name
- DIARET SK (NCT02232503)
- Testing
- Studied cohort
- Volunteers
- 4,011 people
- Sponsor
- Novartis Slovakia, s.r.o.
Diabetes Mellitus, Diabetic Retinopathy
A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME)
This study is conducted to evaluate the safety of intravitreal THR-317 administered in combination with ranibizumab, and to assess the efficacy of the combination treatment in improving best-corrected visual acuity (BCVA) and…
- Conditions
- Diabetes Mellitus, Diabetic Retinopathy, Macular Edema
- Trial name
- NCT03499223
- Testing
- Ranibizumab 0.5mg, THR-317 8mg
- Where
- 37 sites in Belgium, France and 5 more
- Volunteers
- 70 people
- Sponsor
- Oxurion
Wet Macular Degeneration
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with…
- Trial name
- NCT03823300
- Testing
- Faricimab, Aflibercept
- Where
- 137 sites in United States, Argentina and 19 more
- Volunteers
- 658 people
- Sponsor
- Hoffmann-La Roche
Diabetic Retinopathy
Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema
The main objectives of this observational study were to describe outcomes, monitoring and treatment patterns of patients with diabetic macular edema in routine clinical practice who are either treatment naïve patients or…
- Trial name
- APOLLON (NCT02924311)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- France
- Volunteers
- 402 people
- Sponsor
- Bayer
Macular Degeneration
Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD)
This is a Phase III, open-label, multicenter extension study of intravitreally administered ranibizumab in subjects with primary or recurrent subfoveal choroidal neovascularization (CNV) secondary to AMD who have completed the…
- Trial name
- NCT00095433
- Testing
- rhuFab V2 (ranibizumab)
- Volunteers
- 100 people
- Sponsor
- Genentech, Inc.
Macular Degeneration
12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)
The purpose of this 12 week, open-label study is to investigate the safety and efficacy of a single dose regimen of pazopanib eye drop for neovascular AMD.
- Trial name
- NCT01362348
- Testing
- pazopanib eye drops
- Where
- 15 sites in United States, France and 1 more
- Volunteers
- 19 people
- Sponsor
- GlaxoSmithKline
Neovascular Age Related Macular Degeneration
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
The purpose of this study is to evaluate the safety and efficacy of topical ophthalmic squalamine lactate eye drops in treating patients with neovascular age-related macular degeneration (wet AMD), a degenerative retinal eye…
- Trial name
- NCT01678963
- Testing
- Squalamine lactate, Vehicle control
- Where
- 20 sites in United States
- Volunteers
- 142 people
- Sponsor
- Ohr Pharmaceutical Inc.
Geographic Atrophy
A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251
This study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
- Trial name
- NCT05626114
- Testing
- OpRegen
- Where
- 17 sites in United States, Israel
- Volunteers
- 60 people
- Sponsor
- Genentech, Inc.
wetAMD
Canadian Treat and Extend Analysis Trial With Ranibizumab
This is an observational study to will evaluate and compare two Ranibizumab treatment regimens (Standard of care) in patients with neovascular (wet) age-related macular degeneration (wAMD) aiming to achieve and to maintain a…
- Trial name
- CAN-TREAT (NCT02103738)
- Testing
- 0.5 mg Ranibizumab intravitreal injections
- Where
- 24 sites in Canada
- Volunteers
- 505 people
- Sponsor
- Novartis Pharmaceuticals
Intraocular Inflammation, Retinal Vascular Occlusion
Analysis of Imaging Features From Patients Treated With Brolucizumab in the Post-marketing Setting With Reports of Retinal Vasculitis and/or Retinal Vascular Occlusion
This non-interventional descriptive study was undertaken to better understand the most common imaging features associated with inflammation arising in the post-marketing setting when brolucizumab was prescribed in routine…
- Trial name
- NCT05657158
- Testing
- Brolucizumab
- Where
- Switzerland
- Volunteers
- 198 people
- Sponsor
- Novartis Pharmaceuticals